Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Lewis

Showing results (421-430 of 433) with videos related to

Pageof 44
Sort By:
Nature Immunology|July 19, 2022
Author Correction: Hypoxia shapes the immune landscape in lung injury and promotes the persistence of inflammationAnanda S Mirchandani, Stephen J Jenkins, Calum C Bain, et al.
Frontiers in Cell and Developmental Biology|December 26, 2022
The different clinical facets of <i>SYN1</i>-related neurodevelopmental disordersIlaria Parenti, Elsa Leitão, Alma Kuechler, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 11, 2017
Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's SyndromeRohan Sharma, Valerie M Harris, Joshua Cavett, et al.
Brain : a Journal of Neurology|February 22, 2022
Assessing the landscape of STXBP1-related disorders in 534 individualsJulie Xian, Shridhar Parthasarathy, Sarah M Ruggiero, et al.
Nucleic Acids Research|December 2, 2020
The Human Phenotype Ontology in 2021Sebastian Köhler, Michael Gargano, Nicolas Matentzoglu, et al.
Clinical Immunology (Orlando, Fla.)|April 26, 2016
Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndromeValerie M Harris, Rohan Sharma, Joshua Cavett, et al.
Clinical Immunology (Orlando, Fla.)|December 2, 2017
Corrigendum to "Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome" [Clin. Immunol. 168 (2016) 25-29]Valerie M Harris, Rohan Sharma, Joshua Cavett, et al.
Haematologica|May 14, 2026
Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencingWendy Osborne, Euan Haynes, William Wilson, et al.
Medrxiv : the Preprint Server for Health Sciences|January 27, 2025
The natural history of CDKL5 deficiency disorder into adulthoodAngel Aledo-Serrano, David Lewis-Smith, Helen Leonard, et al.
Blood Advances|December 21, 2023
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK studyAnn Tivey, Rohan Shotton, Toby A Eyre, et al.
Pageof 44

Showing results (421-430 of 433) with videos related to

Sort By:
Pageof 44
Nature Immunology|July 19, 2022
Author Correction: Hypoxia shapes the immune landscape in lung injury and promotes the persistence of inflammationAnanda S Mirchandani, Stephen J Jenkins, Calum C Bain, et al.
Frontiers in Cell and Developmental Biology|December 26, 2022
The different clinical facets of <i>SYN1</i>-related neurodevelopmental disordersIlaria Parenti, Elsa Leitão, Alma Kuechler, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 11, 2017
Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's SyndromeRohan Sharma, Valerie M Harris, Joshua Cavett, et al.
Brain : a Journal of Neurology|February 22, 2022
Assessing the landscape of STXBP1-related disorders in 534 individualsJulie Xian, Shridhar Parthasarathy, Sarah M Ruggiero, et al.
Nucleic Acids Research|December 2, 2020
The Human Phenotype Ontology in 2021Sebastian Köhler, Michael Gargano, Nicolas Matentzoglu, et al.
Clinical Immunology (Orlando, Fla.)|April 26, 2016
Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndromeValerie M Harris, Rohan Sharma, Joshua Cavett, et al.
Clinical Immunology (Orlando, Fla.)|December 2, 2017
Corrigendum to "Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome" [Clin. Immunol. 168 (2016) 25-29]Valerie M Harris, Rohan Sharma, Joshua Cavett, et al.
Haematologica|May 14, 2026
Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencingWendy Osborne, Euan Haynes, William Wilson, et al.
Medrxiv : the Preprint Server for Health Sciences|January 27, 2025
The natural history of CDKL5 deficiency disorder into adulthoodAngel Aledo-Serrano, David Lewis-Smith, Helen Leonard, et al.
Blood Advances|December 21, 2023
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK studyAnn Tivey, Rohan Shotton, Toby A Eyre, et al.
Pageof 44